Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALTS ALT5 Sigma	$6.01 -16.7%	$7.93	$1.55 ▼ $10.95	$129.96M	2.17	1.11 million shs	11.54 million shs
MRVI Maravai LifeSciences	$2.63 +1.0%	$2.42	$1.66 ▼ $9.95	$668.48M	0.28	2.45 million shs	444,981 shs
OPT Opthea	$3.41	$3.41	$1.79 ▼ $6.30	$524.84M	1.12	N/A	N/A
SNDL SNDL	$2.08 -1.7%	$1.47	$1.15 ▼ $2.40	$547.90M	3.57	2.11 million shs	3.07 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALTS ALT5 Sigma	+3.59%	-11.86%	+0.56%	+6.03%	+321.64%
MRVI Maravai LifeSciences	-5.45%	+28.08%	+0.39%	+23.81%	-68.37%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	+47.62%
SNDL SNDL	-1.40%	+26.35%	+39.74%	+56.30%	-2.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALTS ALT5 Sigma	0.6327 of 5 stars	0.0	4.0	0.0	3.2	0.0	0.0
MRVI Maravai LifeSciences	3.705 of 5 stars	3.1	3.0	4.4	1.1	0.8	0.6
OPT Opthea	0.4012 of 5 stars	1.1	0.0	0.0	2.6	0.8	0.6
SNDL SNDL	2.2224 of 5 stars	2.0	3.0	0.0	3.8	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALTS ALT5 Sigma	0.00	N/A	N/A	N/A
MRVI Maravai LifeSciences	2.25	Hold	$5.75	119.05% Upside
OPT Opthea	2.17	Hold	$1.33	-60.90% Downside
SNDL SNDL	0.00	N/A	$4.00	92.77% Upside

Current Analyst Ratings Breakdown

Latest ALTS, SNDL, OPT, and MRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/12/2025	MRVI Maravai LifeSciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$7.00 ➝ $5.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALTS ALT5 Sigma	$12.53M	10.36	N/A	N/A	$0.55 per share	10.92
MRVI Maravai LifeSciences	$259.18M	2.58	$0.59 per share	4.45	$1.84 per share	1.43
OPT Opthea	$87.67K	5,986.77	N/A	N/A	($0.56) per share	-6.09
SNDL SNDL	$671.81M	0.81	N/A	N/A	$2.99 per share	0.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALTS ALT5 Sigma	-$6.24M	N/A	0.00	∞	N/A	-74.89%	-179.27%	-16.28%	N/A
MRVI Maravai LifeSciences	-$144.85M	-$1.36	N/A	N/A	N/A	-90.03%	-17.60%	-9.30%	N/A
OPT Opthea	-$220.24M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/29/2025 (Estimated)
SNDL SNDL	-$69.18M	-$0.27	N/A	N/A	N/A	-10.38%	-8.58%	-7.23%	N/A

Latest ALTS, SNDL, OPT, and MRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/31/2025	Q2 2025	SNDL SNDL	-$0.04	$0.01	+$0.05	$0.01	$231.50 million	$179.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALTS ALT5 Sigma	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALTS ALT5 Sigma	1.45	0.88	0.83
MRVI Maravai LifeSciences	0.68	5.16	5.17
OPT Opthea	N/A	1.57	N/A
SNDL SNDL	0.11	5.03	3.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALTS ALT5 Sigma	6.27%
MRVI Maravai LifeSciences	50.25%
OPT Opthea	55.95%
SNDL SNDL	N/A

Insider Ownership

Company	Insider Ownership
ALTS ALT5 Sigma	4.90%
MRVI Maravai LifeSciences	2.11%
OPT Opthea	3.20%
SNDL SNDL	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALTS ALT5 Sigma	170	21.61 million	20.55 million	N/A
MRVI Maravai LifeSciences	610	254.66 million	249.29 million	Optionable
OPT Opthea	8	153.91 million	148.99 million	Not Optionable
SNDL SNDL	2,516	262.78 million	N/A	Optionable

ALTS, SNDL, OPT, and MRVI Headlines

Recent News About These Companies

Form 13G SNDL Inc. For: 14 August

August 14 at 9:28 PM | investing.com

SNDL (NASDAQ:SNDL) Sees Strong Trading Volume - Here's What Happened

August 13 at 1:34 PM | marketbeat.com

Top Canadian Marijuana Stocks If Federal Reform Passes In The USA

August 13 at 11:00 AM | marijuanastocks.comM

Investors Buy Large Volume of SNDL Call Options (NASDAQ:SNDL)

August 13 at 10:51 AM | marketbeat.com

Traders Purchase Large Volume of Call Options on SNDL (NASDAQ:SNDL)

August 13 at 2:15 AM | americanbankingnews.com

Explainer-How US Marijuana Reclassification Could Help Cannabis Companies

August 12 at 7:00 PM | usnews.com

SNDL (NASDAQ:SNDL) Shares Gap Up - Here's What Happened

August 12 at 4:58 PM | marketbeat.com

SNDL INC (SNDL) Is Attractively Priced Despite Fast-paced Momentum

August 5, 2025 | zacks.com

Atb Cap Markets Forecasts SNDL's Q4 Earnings (NASDAQ:SNDL)

August 4, 2025 | marketbeat.com

SNDL (NASDAQ:SNDL) Issues Earnings Results, Beats Expectations By $0.05 EPS

August 3, 2025 | marketbeat.com

SNDL Inc. Earnings Call: Positive Milestones Amid Challenges

August 2, 2025 | msn.com

SNDL Inc. (SNDL) Expands North American Reach with $32.2M Cannabis Retail Acquisition

August 2, 2025 | finance.yahoo.com

SNDL Inc. (NASDAQ:SNDL) Q2 2025 Earnings Call Transcript

August 1, 2025 | msn.com

SNDL Rallies 20% On Strong Q2 2025 Financial Performance

August 1, 2025 | seekingalpha.com

SNDL Inc.: SNDL Announces 2025 Annual and Special Meeting Results

August 1, 2025 | finanznachrichten.de

SNDL Inc (SNDL) Q2 2025 Earnings Call Highlights: Record Profitability and Strategic Growth ...

August 1, 2025 | finance.yahoo.com

SNDL Announces Successful Outcomes of 2025 Annual Meeting

August 1, 2025 | msn.com

SNDL stock jumps as income turns positive for the first time

August 1, 2025 | msn.com

SNDL Inc. (SNDL) Q2 2025 Earnings Call Transcript

July 31, 2025 | seekingalpha.com

SNDL Announces 2025 Annual and Special Meeting Results

July 31, 2025 | prnewswire.com

Top Canadian Pot Stocks Gaining Attention in August 2025

July 31, 2025 | marijuanastocks.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALTS, SNDL, OPT, and MRVI Company Descriptions

ALT5 Sigma NASDAQ:ALTS

$6.00 -1.21 (-16.71%)

As of 02:48 PM Eastern

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Maravai LifeSciences NASDAQ:MRVI

$2.62 +0.03 (+0.96%)

As of 02:48 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Opthea NASDAQ:OPT

$3.41 0.00 (0.00%)

As of 08/14/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

SNDL NASDAQ:SNDL

$2.08 -0.04 (-1.66%)

As of 02:48 PM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time